

<https://www.wabipacademy.com/publications/abstracts/wcbip2022/131-wcbip-congress-2022-published-abstracts/file>.

3. Pallenberg ST, Pust MM, Rosenboom I, et al. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome. *Microbiol Spectr*. 2022;10(5):e01454-22.
4. Doligalski CT, McKinzie CJ, Yang A, et al. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients. *Pharmacother J Hum Pharmacol Drug Ther*. 2022;42(7):580-584.
5. Spoletini G, Gillgrass L, Pollard K, et al. Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. *J Cyst Fibros*. 2022;21(6):1061-1065.
6. Ishimaru D, Boudko D, Meleshkevitch EA, et al. Functional Rescue of CFTR by Aerosolized Delivery of Optimized CFTR mRNA Using ReCode-LNPs in Primary Human Bronchial Epithelial Cells Derived from Patients with Cystic Fibrosis. In: D109. AIRWAY OF INTEREST: EPITHELIAL AND SMOOTH MUSCLE FUNCTION IN HEALTH AND DISEASE. American Thoracic Society; 2022:A5488-A5488.
7. Piotrowski-Daspit AS, Barone C, Lin CY, et al. In vivo correction of cystic fibrosis mediated by PNA nanoparticles. *Sci Adv*. 2022;8(40):eabo0522.
8. Global strategy for the diagnosis, management and prevention of COPD; 2023. Navštíveno: 7. 5. 2023. Dostupné z: <https://goldcopd.org/2023-gold-report-2/>
9. Frazier WD, DaVanzo JE, Dobson A, et al. Early Initiation of non-invasive ventilation at home improves survival and reduces healthcare costs in COPD patients with chronic hypercapnic respiratory failure: A retrospective cohort study. *Respir Med*. 2022;200:106920.
10. Brat K, Koblížek V. Stanovení prognózy pacienty s CHOPN – význam pro klinickou praxi a jak na to. *Stud Pneumol Phthiseol*. 2022;82(2):56-64.
11. McDonald VM, Gibson PG. Treatable traits in asthma: moving beyond diagnostic labels. *Med J Aust*. 2022;216(7):331-333.
12. Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. *N Engl J Med*. 2022;386(2):157-171.
13. Jendzjowsky N, Laing A, Malig M, et al. Long-term modulation of airway remodelling in severe asthma following bronchial thermoplasty. *Eur Respir J*. 2021;59(1):2100622.
14. Tyson L, Hardeman W, Marquette M, et al. A systematic review of the characteristics of interventions that promote physical activity in adults with asthma. *J Health Psychol*. 2022;27(12):2777-2796.
15. Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. *Lancet*. 2022;400(10354):769-786.
16. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2022;205(9):e18-e47.
17. Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2020;202(3):e36-e69. Erratum in: *Am J Respir Crit Care Med*. 2022;206(4):518.
18. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;58(6):2004079.
19. Brat K. Nové diagnostické a léčebné postupy u maligního pleurálního výpotku. *Onkologie*. 2023;17(1):16-21.
20. Lu P, Sun Y, Liang B, Yu L. Derivation and validation of a 18 F-FDG PET/CT scoring model to predict malignant pleural effusion. *Nucl Med Commun*. 2022;43(2):177-185.
21. Sundaralingam A, Bedawi EO, Harriss EK, et al. The Frequency, Risk Factors, and Management of Complications From Pleural Procedures. *Chest*. 2022;161(5):1407-1425.
22. Luengo-Fernandez R, Landeiro F, Hallifax R, et al. Cost-effectiveness of ambulatory care management of primary spontaneous pneumothorax: an open-label, randomised controlled trial. *Thorax*. 2022;77(9):913-918.
23. Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIa Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. *J Clin Oncol*. 2023;41(10):1830-1840.
24. Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. *Lancet Respir Med*. 2023;11(4):354-366.
25. de Langen AJ, Johnson ML, Mazieres J, et al., CodeBreak 200 Investigators. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. *Lancet*. 2023;401(10378):733-746.
26. Goldman JW, Dvorkin M, Chen Y, et al. CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2021;22(1):51-65.
27. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. *Lancet*. 2021;397(10272):375-386.
28. World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Cited: 6. 5. 2023. Available from: <https://www.who.int/publications/i/item/WHO-UCN-TB-2022-2>
29. Günther G, Ruswa N, Keller PM. Drug-resistant tuberculosis: advances in diagnosis and management. *Curr Opin Pulm Med*. 2022;28(3):211-217.
30. Nyang'wa BT, Berry C, Kazounis E, et al.; TB-PRACTECAL Study Collaborators. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. *N Engl J Med*. 2022;387(25):2331-2343.
31. Conradie F, Bagdasaryan TR, Borisov S, et al.; ZeNix Trial Team. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. *N Engl J Med*. 2022;387(9):810-823.
32. Suska K, Amati F, Sotgiu G, et al. Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis. *ERJ Open Res*. 2022;8(4):00060-2022.

# Připravujeme do Vnitřního lékařství

2023

6

- HLAVNÍ TÉMA: Alergologie a imunologie
- Multimorbidita při akutním poškození a selhání ledvin
- Endoskopická a chirurgická léčba obezity
- Vnútrohruďná infekcia vyvolaná baktériou *Delftia acidovorans* – kazuistika
- Subklinická hypotyreóza ve zkratce
- Diferenciální diagnostika kožních krvácivých projevů

▼  
VYJDE  
V ŘÍJNU